FDMT241018P20000
- 6.07
- 0.000.00%
4D Molecular Therapeutics Newsroom
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
4D Molecular Therapeutics Analyst Ratings
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $82
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $79
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
4D Molecular Therapeutics (FDMT) Receives a Buy From RBC Capital
The Latest Analyst Ratings For 4D Molecular Therapeutics
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), 4D Molecular Therapeutics (FDMT) and Cullinan Management (CGEM)
Buy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising Pipeline
RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)
Analysts Conflicted on These Healthcare Names: Senseonics Holdings (SENS), PepGen Inc. (PEPG) and 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
Buy Rating for 4D Molecular Therapeutics: Promising Future Based on Product Efficacy and Strategic Growth Prospects
4D Molecular Therapeutics Price Target Maintained With a $40.00/Share by RBC Capital
4D Molecular Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Strong Buy Rating for 4D Molecular Therapeutics Backed by Promising WAMD Treatment Efficacy and Safety